C-Path Reaffirms Commitment to Advancing Regulatory Science for Disease-Modifying Therapies in Type 1 Diabetes

▤ Summary

Critical Path Institute reaffirmed its role in building regulatory-science and evidence frameworks for type 1 diabetes therapies after the FDA’s accelerated approval of Tzield. The article highlights C-Path’s expansion of the C-peptide evidence base to 74 trials and its ongoing engagement with regulators. It also emphasizes the need for shared, precompetitive standards to define clinically meaningful benefit and support future disease-modifying therapies across multiple stages of T1D. This creates a broader infrastructure conversation for sponsors, regulators, and research partners working in diabetes drug development.

▦ Linked Companies